Nohla Therapeutics Inc., a Seattle, Washington-based biotechnology company, announced the initial closing of a $43.5M Series A financing round.
The round, which brought total financing obtained since inception to $64.6m, was led by new investor Arch Venture Partners with participation from 5AM Ventures and existing investor the Jagen Group. As part of the transaction, Dr. Steven Gillis, a Managing Director at ARCH Venture Partners, and Dr. Brian Daniels, a Venture Partner at 5AM Ventures, will join Nohla’s Board of Directors as Chairman and Director respectively.
The company intends to use the funds to advance its two lead programs (NLA-101 and NLA-102) generated by its novel technology platform, which was spun-out of the Fred Hutchinson Cancer Research Center (The Hutch) in September 2015.
Led by founder and Chief Medical Officer Dr. Colleen Delaney and interim Chief Executive Officer Michael Sistenich, Nohla Therapeutics is advancing universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers.
To date, over 100 patients have been treated across multiple clinical studies using its products, which can be used on demand, without the need for HLA matching, and can promote hematopoietic and immune cell recovery in patients at risk for neutropenia and infection after intensive chemotherapy
and/or radiation treatment for critical diseases.
The company is currently evaluating these cryopreserved expanded cell products in NLA-101, a multicenter, randomized open label Phase IIb study in the setting of myeloablative cord blood transplant. In addition, it plans to evaluate its product in and NLA-102, a Phase II randomized study in the setting of high dose chemotherapy for Acute Myelogenous Leukemia (AML).